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Abstract
Objectives: Statin therapy has been associated with a decreased incidence of venous
thromboembolism (VTE) in clinical trials and enhanced thrombus resolution in animal
models. The effect of statins on thrombus resolution has not been reported clinically. This
study investigates the association of statins with thrombus resolution or improvement in
patients with deep vein thrombosis (DVT).

Methods: A retrospective study of the electronic medical records of consecutive adult
patients presenting with lower extremity DVT was performed. Patients were divided into
two groups based on statin therapy (statin group) or lack thereof (non-statin group). The
two groups were compared with respect to demographics, comorbidities, and risk factors
for VTE. Initial as well as all subsequent ultrasound reports were reviewed for each
patient to determine extent of DVT and subsequent change in thrombus characteristics.
Long-term outcomes examined were thrombus improvement or resolution on follow up
ultrasound, VTE recurrence, mortality. Multivariable analysis was used to determine
independent predictors of thrombus resolution or improvement, VTE recurrence, and
mortality.

Results: A total of 818 patients with DVT were identified [statin group: n = 279 (34%),
non-statin group: n = 539 (66%)]. The patients in the statin group were significantly older
(P < .001). Patients on statin were more likely to have risk factors for and manifestations
of atherosclerosis and to be on antiplatelet therapy (P < .001) while those in the non-statin
group were more likely to have a hypercoagulable disorder (P = .009) or prior DVT (P
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= .033). There was no significant difference in provoked DVT, extent of DVT, or
association with PE (pulmonary embolus), but patients on statin were more likely to have
high-risk PE (P = .046). There was no difference in patients receiving anticoagulation,
type and duration of anticoagulation, inferior vena cava filter placement, or treatment
with lytic therapy. There was no difference in thrombus resolution, mortality, or
recurrence of DVT, PE, or VTE between the groups. On multivariable analysis, age,
proximal DVT, CAD, and cancer were associated with higher mortality while
anticoagulation with warfarin and DOACs and antiplatelet therapy were associated with
lower mortality. Statin therapy, antiplatelet therapy and younger age were associated with
thrombus resolution or improvement.

Conclusions: Statin therapy is associated with greater thrombus resolution or
improvement in patients with DVT. However, statin therapy in this study was not
associated with different clinical outcomes of VTE recurrence or mortality.
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Introduction:
Venous thromboembolism (VTE) is a common condition affecting hundreds of thousands
of patients every year, including those with deep vein thrombosis (DVT) and pulmonary
embolism (PE), a potentially life-threatening condition.1 Patients with VTE are often
managed using anticoagulation agents, the medications of choice for the prevention and
treatment of VTE, however there remains an unmet need for those who cannot tolerate
their side effects or may be inadequately treated. Studies suggest that statins, also known
as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors and most
commonly known for their cholesterol-lowering effects, may also play a role in reducing
the risk of initial or recurrent DVT.2,3 In addition, population studies of VTE patients on
statins have shown that longer duration of statin use is also associated with greater
reduction of recurrent VTE.4 The precise mechanisms of this observed antithrombotic
effect have been explored in a variety of preclinical experiments. In animals, atorvastatin
and rosuvastatin have been shown to reduce venous thrombus burden and DVT-induced
vein wall scarring, while simvastatin has been found to promote thrombus resolution in a
leporine posterior vena cava thrombus model.5,6 Clinically, residual vein thrombosis has
been shown to be a risk factor for VTE recurrence.7 Thus, it is plausible that the effects of
statins on VTE recurrence are potentially mediated by enhancing thrombus resolution.
However, the effect of statins on thrombus remodeling has not been studied clinically.
The following sections review both the nonclinical and clinical literature supporting the
above concepts to establish the context and rationale for the work performed in this
thesis.
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Anti-thrombotic effects of statins on the coagulation cascade
Statins are most commonly known for their efficacy in the management of
hyperlipidemia and its associated sequelae (i.e. coronary artery disease), and have also
shown to significantly reduce the risk of major cardiovascular events.8 However, statins
have also been shown to provide cardiovascular benefit via a number of “pleiotropic”
effects independent from cholesterol lowering, notably including anti-thrombotic
properties at multiple levels of the coagulation cascade. 9 The lipophilic statins
simvastatin and fluvastatin (but not the hydrophilic pravastatin) decrease tissue factor
(TF) expression in macrophages via nuclear factor κB (NF-κB) inhibition in vitro, an
effect which was not reversed by the addition of cholesterol, suggesting that statin’s
effect on TF occurs independently of intracellular cholesterol lowering. Instead, a
different downstream product, geranylgeranyl pyrophosphate (GGPP) is thought to play a
crucial role in the regulation of TF expression. 10 As TF expression has been shown to be
upregulated in lipid-laden macrophages at the core of atherosclerotic plaques and is
thought to promote intravascular thrombosis, the down-regulating effect of statins on TF
would explain another cholesterol-independent aspect of statins’ cardioprotective
properties.11 Indeed, a study in humans found that carotid artery plaques removed from
patients treated with atorvastatin for 4-6 months had significantly lower TF antigen levels
and activity as compared with those on placebo.12

Further downstream in the coagulation cascade is thrombin, the key to activating
thrombus formation and the common target of several marketed anticoagulant therapies.
Statins, particularly atorvastatin, simvastatin, and pravastatin, have been shown in both
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experimental and clinical studies to decrease thrombin formation, however measurements
of thrombin markers such as prothrombin fragments 1.2 (F1.2) and thrombinantithrombin complex (TAT) have yielded less consistent findings, ranging between mild
to neutral effects. This effect is particularly notable in patients with
hypercholesterolemia, where even 3-days of simvastatin (40mg/d) treatment in fourteen
men with LDL cholesterol levels >130 mg/dL on low-dose aspirin (75mg/d) resulted in a
significantly reduced level of prothrombin activation at sites of microvascular injury,
accompanied by delayed Factor Va generation and accelerated activated Protein Cmediated Factor Va inactivation, on top of the anticoagulant effects of aspirin alone. 13-15

To a lesser degree of scientific concordance, statins have also been found to exert antithrombotic effects on the coagulation cascade via decreased fibrinogen cleavage,
decreased Factor XIII activation, increased thrombomodulin expression, and increased
Factor Va inactivation.16-18 Other pleiotropic effects of statins include improved
endothelial function via increased nitric oxide bioavailability, inflammation suppression,
atherosclerotic plaque stabilization, immune-modulation, inhibition of cardiac
hypertrophy, and reduced smooth muscle cell proliferation. 16 These mechanisms, in
concert with each other, are likely to underpin the anti-thrombotic and vascular protective
effects observed in animal and clinical studies.

Statins and the risk of venous thromboembolism
The clinical relevance of the antithrombotic effects of statins has been investigated by
many studies. In 2000, the Heart and Estrogen/Progesterone Replacement Study (HERS)
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found in a secondary analysis of the impact of hormonal therapy on the risk of VTE that
use of statins (but not any other lipid-lowering drug) in a postmenopausal population was
associated with a decreased risk of VTE (relative hazard 0.5 [0.2 – 0.9]).19 In 2001, Ray
et al. showed through a large Canadian retrospective cohort study that any dose of statin
use in individuals greater than 65 years old was associated with a 22% lowered incidence
of venous thromboembolisms.20 This association has been supported by a number of
case-control, cohort, or observational studies, including studies finding statin-associated
VTE risk reduction in patients with underlying hypercoagulable states such as cancer and
nephrotic syndrome.21-23 One study by Ramcharan et al. found that different statin types
and treatment durations were all associated with a decreased risk of VTE (OR 0.45 [0.36
– 0.56]).23 However, not all studies have found a positive association between statins and
reduced VTE risk, including a population-based retrospective follow-up nested casecontrol analysis of the United Kingdom’s General Practice Research Database and a
prospective open cohort study in England and Wales.24,25 Considering the divergent
findings in these various retrospective studies, perhaps the single most important trial is
then the randomized, double-blinded, placebo-controlled Justification for the Use of
statins in Prevention: an Interventional Trial Evaluating Rosuvastatin (JUPITER) study
published in 2009. In the JUPITER study, the trialists found that 20 mg/d of rosuvastatin
reduced the risk of VTE in asymptomatic patients (men over 50 years old and women
over 60 years old) with no evidence of cardiovascular disease, LDL-cholesterol <130
mg/dL, and CRP >2 mg/L (at first visit) over the course of 1.9-years of follow-up. The
study found significant reductions in DVT or PE (34 events in the treatment arm vs 60
events in the placebo arm, HR 0.57 [0.37–0.86]), with the largest reduction in isolated
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DVT (55%), however failed to reduce the occurrence of PE (OR: 0.77 [ 0.41–1.46]) or
VTE death (OR: 0.50 [0.20–1.24]).2 A meta-analysis of 4 cohort and 4 case-control
studies published in 2011 by Pai et al. sought to expand investigation beyond the healthy
older adults studied in JUPITER to include a more heterogeneous (younger or comorbid)
populations. Pai et al. found that while statin use was significantly associated with a
lower rate of VTE (OR 0.67; 95% CI 0.53 – 0.84), its association with lower rate of DVT
(OR 0.53; 95% CI 0.22 – 1.29) did not meet significance and was likely attributable to a
small sample size. The body of evidence taken together suggest that while statins’ effect
on reducing VTE may be variably observed based on population and underlying medical
comorbidities, the possibility of a clinically meaningful association deserves further
study.

Residual thrombus in DVT and the post-thrombotic syndrome
There is a myriad of risk factors associated with the recurrence of VTE, and one of
interest is residual venous thrombus. Many studies have attempted to understand the
individual risk of VTE recurrence to better align treatment duration with patient-specific
benefit-risk profiles. In a 2011 systematic review, Tan et al. found that residual
thrombosis was positively associated with VTE recurrence, suggesting that assessing
residual venous obstruction may be useful in individual risk assessment. 26 However, this
finding did not seem to translate to clinical management, as the contemporaneously
conducted REVERSE cohort study by L. E. Gal et al. did not find a significantly higher
risk of recurrent VTE in patients who were found to have residual thrombus at the time of
completing 5-7 months of anticoagulant therapy.27 While this finding does not support
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the assessment for residual thrombus in the clinical determination of individual treatment
duration, the presence of a residual thrombus remains pathologically significant given the
chronic sequelae of venous hypertension and vein wall scarring which characterizes postthrombotic syndrome (PTS).28,29 In PTS, typical symptoms include pain, swelling, and
cramping of the leg, generally worsened when standing, and in severe cases can lead to
venous ulceration. Despite optimal anticoagulation by conventional therapies, many
patients with iliofemoral venous thrombosis continue to develop PTS, highlighting an
unmet medical need, particularly around thrombus resolution. While the prevention of
PTS is rooted in DVT prevention and the active management of incident DVT’s, cases of
extensive DVT can be treated with open or endovascular thrombus removal (e.g.
catheter-directed thrombolysis).28,30 In the 2016 CaVenT trial, Haig et al. showed that
patients randomized to catheter-directed thrombolysis by alteplase within 21 days from
symptom onset plus standard therapy (anticoagulation therapy and compression
stockings) were less likely to develop PTS compared to those on standard therapy alone
at 5 years follow-up.31 This supports the notion that thrombus resolution may be
associated with improved outcomes and suggests that in the absence of intervention
(which may not be universally accessible) there may be a role for medications that
promote thrombus resolution beyond currently available anticoagulants.

Statins and thrombus resolution
In addition to its lipid-lowering and antithrombotic effects, statins have also been found
to improve the resolution of venous thrombi. In a murine study published in 2015,
Kessinger et al. demonstrated a 25% thrombus burden reduction in mice with stasis-
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induced (IVC ligation) venous thrombi treated with atorvastatin or rosuvastatin, which
was accompanied by a significant reduction in platelet aggregation and clot stability, as
well as anti-inflammatory effects most notable early after thrombus formation, and a 50%
reduction in thrombus-induced vein wall scarring.5 A similar model in rabbits was later
studied by Feng et al., finding that simvastatin increased thrombus resolution, likely
through anti-inflammatory effects independent of its lipid-lowering properties.6 The
authors also noticed that simvastatin affected thrombus size sooner than low molecular
weight heparin (3-day vs 14-day), with effects equalizing in the 14-day arm, likely
explained by their different mechanisms of action. These preclinical models suggest that
statins may be an effective treatment in patients with VTE who cannot otherwise tolerate
currently available options for anticoagulation. While there is evidence from a single case
report of aggressive combination statin and antiplatelet therapy leading to rapid
regression of an unstable mobile thrombus aortic atheroma, no other clinical studies have
been reported exploring the effect of statins on thrombus resolution in humans. 32
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Aim
Based on a comprehensive review of the literature above, statins appear to have a strong
mechanistic rationale supporting clinical findings of its anti-thrombotic effects in
preventing VTE, however when it comes to resolution of an incident VTE, only animal
trials have been conducted. This study hypothesizes that statins are associated with
greater thrombus resolution or improvement in humans. The aim of this study is to
investigate thrombus resolution and improvement in a group of patients treated for DVT
while on statin compared to patients not receiving statin. Thrombus resolution and
clinically significant recurrence of VTE will be correlated with statin use.
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Methods:
Study design
This is a retrospective study examining consecutive adult patients (age ≥ 18) presenting
with newly diagnosed acute lower extremity DVT at an academic tertiary care center
from January 2013 through April 2014. The study protocol and waiver of informed
consent was approved by the human investigation committee. Patients were divided into
2 groups based on their use of statin therapy or lack thereof, and all patient records and
ultrasound reports were reviewed. Patients initiating statins after developing DVT were
considered to not have a standing history of statin use and were included in the non-statin
group for initial presentation but were analyzed with the statin group for long-term
outcomes. Patients who had continuous statin use prior to DVT incidence but
discontinued after were included in the statin group for initial presentation but were
analyzed with the non-statin group for outcomes.

Variables
Patient demographics and comorbidities as well as ultrasound characteristics were
extracted from the electronic medical records. Patients’ age, sex, history of
hypercoagulable disorders, hypertension, congestive heart failure (CHF), diabetes,
hyperlipidemia, coronary artery disease (CAD), peripheral arterial disease (PAD),
cerebral vascular disease (CVD), cancer (including metastatic disease where present),
prior DVT, prior pulmonary embolism (PE), and smoking were recorded. In addition to
the aforementioned variables, other risk factors for VTE required to calculate the Caprini
score were also extracted.33 These included concurrent presentation of varicose veins or
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swollen legs, concurrent central venous access, history of inflammatory bowel disease,
sepsis within the past month, pneumonia, chronic obstructive pulmonary disease, long
distance travel, immobilizing plastic cast, multiple trauma, paralysis, major surgery,
elective major lower extremity arthroplasty, and hip, pelvis, or leg fracture. The
prescription of antiplatelets (aspirin, clopidogrel, prasugrel, dipyridamole, ticagrelor,
ticlopidine) and statins at the time of diagnosis was noted.

The DVT characteristics were noted as occlusive vs non-occlusive, proximal vs distal,
and provoked vs unprovoked. Proximal DVT included thrombi in the popliteal vein or
above, while distal DVT included thrombi found exclusively in the tibial veins. Cases
that had thrombi in both the popliteal vein or above and in the tibial veins were
considered proximal. Provoked DVT was defined according to the methodology of
Brownson et al. and included DVTs associated with trauma, recent surgery, sedentary
travel >4 hours, or confinement to bed >72 hours within 30 days of the event, or initiation
of oral contraceptives, or a central venous femoral line (if ipsilateral DVT).34 Associated
PE confirmed by imaging was classified by severity. High-risk PE was defined as >15
min of hypotension (<90 mmHg); intermediate-risk PE was defined by blood pressure
>90 mmHg with accompanying right ventricular dysfunction (dilation or elevated Nterminal pro brain natriuretic peptide >500 pg./mL or brain natriuretic peptide >90
pg/mL) or myocardial necrosis (troponin I >0.4 ng/mL or troponin T >0.1 ng/mL), and
finally low-risk PE was defined by the lack of these characteristics.35 Cases without
definitive imaging but where PE was highly suspected by the treating physician were also
noted.
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The treatment of DVT was reviewed for the type of anticoagulation therapy [warfarin,
low molecular weight heparin (LMWH), or direct oral anticoagulant (DOAC)] and its
duration. Only full-dose anticoagulation therapies with INR goal of 2-3 or more were
noted. The placement of inferior vena cava (IVC) filters and administration of systemic
or catheter-directed thrombolytics were also noted.

Outcomes and Statistical Analysis
The long-term outcomes of mortality, DVT recurrence, PE recurrence, and VTE
recurrence were compared between the 2 groups in follow-up through summer of 2017.
The patients who underwent repeat lower extremity venous ultrasound after one month of
diagnosis were noted. The repeat ultrasound report was reviewed, and the radiologist
assessment of thrombus burden compared to the initial ultrasound was noted as:
progressed (worsened), stable, improved, or completely resolved. The number of repeat
ultrasound exams varied by patient and thrombus burden may have changed or resolved
prior to the final repeat ultrasound, so we noted the date and results of the earliest repeat
ultrasound after one month of diagnosis where no further change in thrombus status was
observed in subsequent exams. Patients who died during follow-up were excluded from
analysis of VTE recurrence. A multivariable analysis was then used to determine the
independent factors associated with thrombus improvement or resolution, VTE
recurrence, and mortality. Factors that were included in the model consisted of age, sex,
provoked vs unprovoked DVT, distal vs proximal DVT, history of DVT, history of PE,
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smoking, anticoagulation therapy (warfarin, LMWH, or DOAC), antiplatelet therapy,
hypertension, CHF, diabetes, hyperlipidemia, CAD, PAD, CVD, and cancer.

Statistical analysis
Characteristics of the sample were summarized using descriptive statistics and expressed
as percentages (n) in the case of categorical variables and mean and standard deviation
for continuous variables. Bivariate analyses were conducted using independent samples ttests to compare means and chi-square tests to compare proportions. Multivariable
logistic regression was performed to compare study groups on a dependent bivariate
outcome while adjusting for sample characteristics. Statistical analyses were performed
using SAS version 9.4.

Attribution of work performed
Identification of consecutive adult patients presenting with DVT in the study period was
performed by Nancy Huynh MD, Anand Brahmandam MD, and Kirstyn Brownson MD,
including basic demographic information and characteristics of DVT such as location,
associated PE, anti-thrombotic treatment, and history of underlying hypercoagulable risk
factors (e.g. cancer, oral contraceptives, immobilization, long travel, surgery, et cetera).
This data was double-checked by the author Charles Hsu, who then additionally collected
information including comorbidities and past medical history, medication use (including
statin and antiplatelet use), timing of statin initiation relative to presenting DVT,
radiographic reports upon presentation and on subsequent follow-up, and long-term
follow-up of outcomes through summer of 2017 (mortality, VTE recurrence). The author
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performed a comparison of radiographic reports between initial and follow-up encounters
to determine change in the status of thrombus burden of DVT. All statistical analysis was
done by Jesse Reynolds in collaboration with Cassius Iyad Ochoa Chaar MD MS and the
author. The author drafted the manuscript for submission to the Journal of Vascular
Surgery: Venous and Lymphatic Disorders and the manuscript was reviewed by Cassius
Iyad Ochoa Chaar MD MS, Alfred Lee MD PhD, Wassim Fares MD MSc, and Jesse
Reynolds MS.
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Results:
Study population
A total of 818 patients with DVT were identified during the study period; 279 (34%)
were on statin therapy at time of presentation and 539 (66%) were not. There were 5
patients who were initiated on statin therapy and another 5 who discontinued statin
therapy shortly after the diagnosis of DVT; these were accounted for in the analysis. The
three most common statin agents were atorvastatin (10 to 80 mg daily), simvastatin (20 to
80 mg daily), and pravastatin (10 to 80 mg daily), which collectively accounted for ~90%
of all statins used. Patients in the statin group were significantly older (72 ± 13 vs 63 ± 17
years) and were more likely to have risk factors and manifestations of atherosclerosis,
including hypertension, CHF, diabetes, hyperlipidemia, CAD, PAD, and CVD. There
was no significant difference in sex, history of cancer, or history of smoking between the
2 groups (Table 1).

More patients in the statin group were on antiplatelet therapy (55% vs 20%). In the statin
group, 130 patients were on single agent antiplatelet therapy (122 aspirin, 8 clopidogrel)
and 24 were on dual agent antiplatelet therapy (21 aspirin and clopidogrel, 3 aspirin and
prasugrel or dipyridamole). In the non-statin group, 97 patients were on single agent
antiplatelet therapy (88 aspirin, 9 clopidogrel), and 10 were on both aspirin and
clopidogrel. One or more hypercoagulable disorders were found in 44 patients across
both groups, the most common including Factor V Leiden (n = 12), antiphospholipid
syndrome (n = 9), antithrombin III deficiency (n = 5), and Protein C deficiency (n = 5).
Patients in the non-statin group had a higher proportion of hypercoagulable disorder or a
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history of prior DVT while the patients in the statin group had significantly higher mean
Caprini scores. Additionally, there was no significant difference in the history of prior PE
(Table 1).

DVT characteristics and treatment
There was a higher proportion of high-risk PE (24% vs 11%, P = .046) in the statin
group. The 2 groups showed no significant difference in provoked DVT, proportion of
proximal DVTs, or association with PE. The groups also showed no significant difference
in the type of anticoagulation received, duration of anticoagulation therapy, IVC filter
placement, and proportion treated by thrombolysis (Table 2).

Long-term outcomes
There was no difference in the overall duration of follow-up between the 2 groups (741 ±
569 days vs 710 ± 565 days, P = .46). The frequency of repeat ultrasound after one month
(39% vs 45%, P = .13) and the intervals at which ultrasounds were performed following
initial presentation were not significantly different (496 ± 408 days vs 530 ± 409 days, P
= .46). There was no significant difference in mortality (41% vs 37%, P = .32) or
resolution or improvement of thrombus on repeat ultrasound between the groups (85% vs
77%, P = .12). There was no statistically significant difference in recurrence of DVT
(15% vs 17%, P = .52), PE (2% vs 4%, P = .41), or VTE (16% vs 19%, P = .43) (Table
3). A subgroup analysis of the characteristics of patients who underwent repeat
ultrasound after one month was performed (Supplement Tables 1 and 2). In this
subgroup, there was no significant difference between the statin and non-statin patients in
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recurrence of DVT, PE, VTE or mortality (Supplement Table 3). On the other hand, a
comparison of the patients who did not receive repeat ultrasound after one month to the
patients that underwent repeat ultrasonography showed significant differences and
selection bias. Patients who did not receive a repeat ultrasound were older, suffered from
more comorbidities, and were less likely to receive anticoagulation or catheter-directed
thrombolysis as treatment for DVT. They had significantly higher mortality, shorter
follow up, and less likelihood of having recurrent VTE (Supplement Tables 4, 5, and 6).
Furthermore, there was no significant difference in time to repeat US between the statin
and non-statin groups when stratified into groups based on thrombus resolution status and
time to repeat US < 1 year, 1 – 2 years, 2 – 3 years, 3 – 4 years, and > 4 years
(Supplement Table 7).

Multivariable analysis
On multivariable analysis, which adjusted for potential confounders including those
variables in Tables 1 and 2, statin therapy (OR 3.23, 95% CI [1.32 – 7.87]) and
antiplatelet therapy (OR 2.25 [1.05 – 4.81]) were found to be independently associated
with thrombus resolution or improvement on ultrasound. Older age (OR 0.97 [0.95 –
0.99]) was found to be associated with lower thrombus resolution or improvement. No
significant association was found between thrombus resolution or improvement and the
following factors: sex, provoked vs unprovoked DVT, distal vs proximal DVT, CAD,
history of cancer, or anticoagulation by warfarin, LMWH, or DOAC as compared with no
anticoagulation (Table 4).
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Distal DVT compared to proximal DVT (OR 0.53 [0.35 – 0.8]), anticoagulation with
warfarin (OR 0.19 [0.12 – 0.3]) or DOACs (OR 0.16 [0.09 – 0.3]) as compared to no
anticoagulation, and antiplatelet therapy (OR 0.57 [0.37 – 0.87]) were all independently
associated with lower mortality. Age (OR 1.04 [1.03 – 1.06]), CAD (OR 3.12 [1.80 –
5.41]), and history of cancer (OR 4.26 [2.91 – 6.25]) were found to be independently
associated with mortality. Mortality outcomes were not associated with statin therapy,
sex, provoked vs unprovoked DVT, or anticoagulation by LMWH as compared to no
anticoagulation (Table 4).

Finally, there was no significant association of any variable with recurrent VTE (Table
4).
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Discussion:
This study found that statin therapy is associated with thrombus resolution or
improvement after DVT, consistent with the literature on statin’s pleiotropic
cardiovascular effects beyond its known lipid-lowering action. However, the
retrospective nature of this study places significant limitations on our ability to draw
inference on causation. On univariate analysis, the statin group was found to have no
significant difference in thrombus characteristics on repeat ultrasound from the non-statin
group, but patients on statins had significantly more cardiovascular comorbidities and
were older. The lack of an overt difference in thrombus resolution or improvement
between the two groups could be attributed to the counterbalancing influence of older age
and possibly greater overall comorbidity impairing or otherwise adversely affecting the
ability of thrombus remodeling. Even though this effect of statins has been described in
animal models, the clinical correlation in humans has not been reported, to our
knowledge.5,6 As established in the introduction, statins have both significant antithrombotic effects and anti-inflammatory properties on the vascular endothelium, which
may explain the enhanced thrombus resolution seen in this study.36 A similar impact was
reported in the arterial circulation in a case report describing a patient having an aortic
mobile atheroma that was treated with high dose statin and dual anti-platelets resulting in
complete resolution of the atheroma on serial echocardiography.32

This study found that the impact on thrombus resolution did not translate into a clinical
effect of decreased recurrent VTE. While this is consistent with the findings of Brækkan
et al., who found a modest but insignificant decrease in recurrent DVTs in patients on
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statins, other studies showed a clearly protective pattern.4,37-39 Smith et al. found a
statistically significant lower risk (26%) of recurrent VTE with statin use. Key
differences in the cohorts may account for the differing results. Smith et al. studied a
larger patient population (n = 4,350) and had a longer mean follow up of 3.4 years. Even
though the incidence of recurrent VTE observed in their study (16%) was similar to that
of our study, the larger sample and longer duration of follow up likely allowed Smith et
al. to demonstrate clinical differences in VTE recurrence that our study did not have
enough power to resolve. Additionally, our current study had a high proportion of cancer
patients (40% vs 23% in Smith et al.) and a high mortality on follow up (40%) decreasing
further the likelihood of the cohort to demonstrate significant differences in VTE
recurrence.39 While the JUPITER randomized trial demonstrated the effect of
rosuvastatin on prevention of VTE in 17,802 patients followed for 1.9 years, the trial
excluded patients with cancer and cardiovascular disease and focused on a population of
“apparently healthy adults” with no history of VTE.2 In a retrospective study of 170,459
patients with cancer followed for up to 1 year, El-Refai et al. found that statins had no
statistically significant protective effects against cancer-associated VTEs in most cancer
types with the exception of DVT in leukemia and PE in colorectal cancer.40 Therefore it
is plausible that the high proportion of cancer in the current study could explain the lack
of association between statins and VTE recurrence.

Since the submission of the original manuscript for publication, additional studies have
been published in the literature exploring topics covered in this thesis. In a 2019 Japanese
study (n = 3027) from the COMMAND VTE Registry, Yoshikawa et al. found that
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patients who were on statins at baseline had a significantly lower cumulative 3-year
incidence of recurrent VTE both before adjusting for potential confounders and after (HR
0.49 [0.29 – 0.78], P = .002), and was insensitive to subgroup analysis with and without
active cancer. Similar to this study, Yoshikawa et al. also found that patients in their
statin group, when compared to the non-statin group had greater age (71 ± 12 vs 67 ± 16,
P < .001), and more cardiovascular risk factors such as CHF, HTN, diabetes, CAD.
Additionally, significantly more patients in their statin group were women (67% vs 60%,
P = .009), and had chronic kidney disease (24% vs 18%, P = .003) and connective tissue
disease (11% vs 7.6%, P = .02). Departing from the results in the present study, a much
lower proportion of patients in both groups had cancer, with far fewer in the statin group
with history of cancer (20% vs 33%, P < .001) as well as active cancer (12% vs 25%, P
< .001). Additionally, they found a greater history of major bleeding in the non-statin
group (4.3% vs 8.2%, P = .005).41 The longer follow-up compared to the present study (3
years vs ~2 years) may explain in part the difference in finding of protection against VTE
recurrence. One plausible hypothesis to explain this difference may be extended from a
concept derived from El-Rafai et al., that a higher cancer proportion in the statin study
group may disfavor finding an association against VTE recurrence, as they generally
found no protective effects of statins against recurrent VTE in multiple cancer
populations. However, the sensitivity analysis conducted by Yoshikawa et al. does not
support this hypothesis, leaving us to believe that more likely the present study was not
adequately powered in sample size or follow-up duration to detect a difference in VTE
recurrence.
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In a 2019 study of data from the RIETE registry of 32,062 VTE patients, Siniscalchi et al.
found that on univariate analysis statin users had a similar risk of VTE recurrence (HR
0.98 [0.82 – 1.17]) and a similar mortality rate (HR 1.01 [0.93 – 1.10]). However, on
propensity score matching, they found that statin users had a significantly lower risk for
death (HR 0.62 [0.48 – 0.79]) while the risk of VTE recurrence remained similar (HR
0.98 [0.61 – 1.57]). The baseline characteristics of the statin and non-statin groups
between Siniscalchi et al. and the present study were also similar, with statin group
patients being older (73 ± 11 vs 63 ± 19, P < .0001), a larger proportion on antiplatelet
therapy (38% vs 11%, OR 5.19 [4.87 – 5.52]), and with significantly more cardiovascular
comorbidities: CHF (13% vs 5.5%, OR 2.65 [2.43 – 2.89]), HTN (75% vs 40%, OR 4.56
[4.30 – 4.84]), CAD (20% vs 3.7%, OR 6.67 [6.11 – 7.29]), CVD (14% vs 4.8%, OR
3.11 [2.84 – 3.40]), and diabetes (30% vs 11%, OR 3.52 [3.30 – 3.75]). Notably, the
proportion of patients with history of cancer in both groups were identical (24%) and
significantly lower than the proportions in the present study (41% vs 44%). 42 The finding
of no association of statins with VTE recurrence is consistent with the results of the
present study, however directly conflicts with the findings of Yoshikawa et al. and other
studies. Given that Siniscalchi et al. studied patient populations with proportions of
cancer within the range found in the Yoshikawa et al. study, we would expect that both
studies would show similar findings, and the fact that no association was found by
Siniscalchi et al. only further preserves the controversy of the topic. They hypothesize
that their observed mortality benefit likely stems from statin’s pleiotropic cardiovascular
effects. On the other hand, the impact of statin therapy on thrombus remodeling was not
specifically studied in any of the recent publications.
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Antiplatelet therapy, namely aspirin, has been shown to decrease the risk of recurrence of
VTEs. The WARFASA study showed that in patients without cancer, aspirin therapy
started after 6-18 months of oral anticoagulation reduced VTE recurrence by 40%.43,44
The present study, which had 40% cancer patients, did not find a significant association
between antiplatelet therapy and VTE recurrence, possibly explained by the previously
discussed loss-of-cohort from a high mortality rate. Given the involvement of platelets in
venous thrombus formation, it is plausible that antiplatelet agents may promote thrombus
resolution in a related manner, as was found to be the case in the current study. However,
further investigation is required to confirm this clinical finding. Finally, antiplatelet
therapy was found to be independently associated with lower mortality in this study,
which is consistent with the Antiplatelet Trialists’ Collaboration report of decreased
overall mortality and rates of myocardial infarction and stroke in patients using
antiplatelet therapy longer than 1 month.45

Considering other factors affecting mortality, the anticoagulant agents warfarin and
DOACs were associated with lower mortality in the setting of DVT, corroborating
clinical evidence to date.46-48 On the other hand, LMWH was not found to be protective,
possibly due to its preferential use as the anticoagulant of choice for DVT in cancer
patients per current treatment guidelines.49

Provoked vs unprovoked DVT did not appear to be independently associated with
recurrent VTE in this study. This is inconsistent with the results of the landmark 2003
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publication by Baglin et al. in which 570 consecutive patients were prospectively
followed for 2 years, and found that patients with unprovoked VTE were at a 2.2-fold
higher risk of recurrence than those with non-surgically provoked events, while none of
the patients with surgically provoked events experienced recurrence.50 In Baglin et al.,
however, key exclusion criteria were malignancy and antiphospholipid syndrome, which
clouds direct comparison with the high cancer proportion in the present study, which may
have been a pathologic confounder if not at least contributing to higher loss-of-cohort due
to mortality.

Distal DVTs were associated with decreased mortality when compared to proximal DVTs
consistent with a prior finding by the Computerized Registry of Patients with Venous
Thromboembolism (RIETE) investigators, who attributed the difference to better clinical
status of patients with isolated distal DVT whose mortality was mainly due to non-VTE
related deaths.51 In a study by Martin et al., proximal DVT was associated with a
significantly higher incidence of associated PE, which may be another factor contributing
to the higher mortality associated with proximal DVTs. 52

Lastly, multivariable analysis found that older age, history of CAD, and history of cancer
were independently associated with higher mortality. These associations are well-known
and provide validation of the analytic approach and model used in this study and greater
credibility to its primary findings.53-55
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The variables in multivariable analysis that yielded high odds ratios with large confidence
intervals may have done so because of limited exposure across groups and we suggest
that these variables be considered in any future retrospective or prospective studies.
Additionally, as proportion of cancer patients appears to be relatively inconsistent across
various trials investigating the effects of statins on recurrence of VTE, future study
should focus on isolating this variable to better elucidate an association or lack thereof.

This study is limited by its retrospective nature. The lack of continuous and consistent
monitoring precluded the opportunity for any meaningful analysis of time to thrombus
change. Such analysis would have helped quantify the differential impact of statin
therapy on the rate of thrombus resolution, potentially offering new insight on the
timescale and/or mechanisms of its effects. Some clinical information may have been
incomplete, or unavailable in the medical records. Specifically, dosages of statins were
not consistently available and could not be considered in analysis. Maintenance of INR
goals of patients on anticoagulation therapy were not tracked, and compliance with
administration of anticoagulation could not be confirmed. Changes in medications
beyond the initial encounter were not reviewed and patient adherence to prescribed
medication regimen could not be verified. Those patients who developed subsequent
VTE or died from PE outside the system could not be captured. Thrombus resolution may
enhance venous return and play a role in mitigating the development of PTS. The patients
in this study were treated and followed by a variety of providers and assessment of PTS
by standard venous disability scoring system was not available. Analysis of patients with
repeat ultrasound greater than one month after diagnosis provides an effective time period
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for anticoagulation therapy to take effect and for us to observe the long-term effects of
thrombus remodeling.56 Finally, decisions to perform ultrasound follow-up were not
based on a pre-defined protocol but rather clinical presentation and different provider
practices. With only approximately half of the patients undergoing repeat ultrasound,
there was a selection bias from the providers caring for the patients (Supplement Tables
4-6). However, selection bias in repeat US would only affect the findings of our study if
they were a different bias in the statin group versus the non-statin group, which in our
supplemental analysis we did not find to be significant. Even though additional analysis
of patients undergoing repeat ultrasound in the statin and non-stating groups of patients
showed similar differences as the entire cohort (Supplement Table 1), it is possible that
selection bias unaccounted for between the 2 groups might have affected the results.

Additionally, patients may have different responses in the anti-thrombotic effects of statin
therapy due to unmeasured differences in their genetic profile. For example, the +5466G
allelic variant of the TF gene, occurring in 16% of individuals of European descent, has
been shown in patients with ischemic heart disease to result in a greater decrease in rate
of thrombin formation after 3-month administration of simvastatin, as compared with
those with the +5466AA genotype.57 Other yet-to-be-discovered pharmacogenetic factors
may influence statin’s cholesterol-lowering, anti-thrombotic, or anti-inflammatory effects
in different patients, potentially leading to differences in the long-term outcomes
measured in this study.

30
The totality of evidence from preclinical studies of statins’ mechanistic influence on
hemostasis suggest that the effect occurs independently of its lipid-lowering effects.
However, the present study and all other retrospective clinical studies to date have been
conducted in patient populations with dyslipidemia, as statin use is clinically warranted
only in the presence of elevated lipid levels (notable exception being the JUPITER trial
involving healthy adults). As a result, the association of thrombus resolution or
improvement with the use of statins in this study cannot be definitively attributed
independent of statins’ lipid-lowering properties.

This work was presented as an oral presentation at the 30 th American Venous Forum,
Tucson, AZ, on February 22, 2018, and subsequently published in the Journal of
Vascular Surgery: Venous and Lymphatic Disorders in March 2019.
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Conclusion:
Statin therapy appears to be associated with enhanced thrombus resolution or
improvement in patients with DVT who underwent repeat ultrasound, however, there was
no association with recurrence of VTE or mortality. The role of statin therapy in the
resolution of venous thrombi and overall treatment of VTE needs to be further
investigated.
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Table 1: Patient characteristics

Age (years ± SD)
Female
Hypertension
Diabetes
Hyperlipidemia
CHF
CAD
PAD
CVD
Hypercoagulable disorder
History of prior DVT
History of prior PE
History of cancer
History of smoking
Antiplatelet therapy
Caprini score ± SD

Statin group
(n = 279)
% (n)
72 ± 13
51 (140)
82 (229)
38 (105)
73 (205)
17 (48)
35 (98)
9 (25)
20 (57)
3 (7)
14 (40)
8 (21)
41 (113)
56 (156)
55 (154)
6.7 ± 2.9

Non-statin group
(n = 539)
% (n)
63 ± 17
52 (278)
50 (268)
17 (92)
14 (76)
10 (55)
9 (51)
2 (11)
7 (38)
7 (37)
20 (110)
11 (60)
44 (235)
56 (301)
20 (107)
6.3 ± 2.8

P value
<0.001*
0.70
<0.001*
<0.001*
<0.001*
0.007*
<0.001*
<0.001*
<0.001*
0.009*
0.03*
0.10
0.40
0.98
<0.001*
0.022*

*Statistically significant P < .05; SD: standard deviation, DVT: deep vein thrombosis,
PE: pulmonary embolism, CHF: congestive heart failure, CAD: coronary artery disease,
PAD: peripheral arterial disease, CVD: cerebral vascular disease
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Table 2: DVT characteristics and treatment

Provoked DVT
DVT location
Distal
Proximal
DVT associated with PE
Severity of PE
Low risk
Intermediate risk
High risk
Anticoagulation
None
Warfarin
LMWH
DOAC
Duration of anticoagulation
< 3 months
3-6 months
6-12 months
> 12 months
Placement of IVC filter
Catheter-directed thrombolysis of DVT
Catheter-directed thrombolysis of PE
Systemic administration of thrombolytic
agent

Statin group
(n = 279)
% (n)
54 (151)

Non-statin
group
(n = 539)
% (n)
48 (260)

25 (69)
75 (209)
29 (80)

27 (144)
73 (395)
25 (135)

36 (29)
40 (32)
24 (19)

39 (52)
50 (67)
11 (15)

24 (67)
50 (139)
15 (41)
11 (32)

20 (108)
47 (254)
18 (97)
15 (80)

P value
0.10
0.56

0.26
0.046*

0.23

0.32
22 (41)
22 (42)
33 (63)
23 (44)
30 (84)
2 (6)
1 (3)
2 (6)

23 (87)
28 (106)
27 (102)
23 (86)
27 (143)
1 (8)
2 (9)
1 (8)

0.28
0.57
0.76
0.57

*Statistically significant P < .05; LMWH: low molecular weight heparin, DOAC: directacting oral anticoagulant, IVC: inferior vena cava, DVT: deep vein thrombosis, PE:
pulmonary embolism
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Table 3: Long-term outcomes

Days to last follow-up Mean ± SD
Median (IQR)
Surviving patients at last follow up
New or recurrent DVT
New or recurrent PE
Recurrent VTE
Mortality
Patients with repeat US > 1 month
Days to repeat ultrasound ± SD
Thrombus characteristics
Resolution / Improvement
Stable / Progression

Statin group
(n = 279)
% (n)
741 ± 569
891 (91 – 1283)
59 (166)
15 (25)
2 (3)
16 (27)
41 (113)

Non-statin
group
(n = 539)
% (n)
710 ± 565
714 (67 – 1250)
63 (340)
17 (59)
4 (12)
19 (65)
37 (199)

39 (110)
496 ± 408

45 (242)
530 ± 409

85 (93)
15 (17)

77 (187)
23 (55)

P value
0.46
0.39
0.52
0.41
0.43
0.32
0.13
0.46
0.12

DVT: deep vein thrombosis, PE: pulmonary embolism, VTE: venous thromboembolism,
SD: Standard deviation
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Table 4: Multivariable analysis
Thrombus
Resolution or
Variable
Improvement
Statin therapy
3.23 [1.32-7.87]*
Age
0.97 [0.95-0.99]*
Female sex
1.6 [0.9-2.84]
Provoked vs
1.31 [0.68-2.53]
unprovoked DVT
Distal vs Proximal
1.77 [0.88-3.57]
DVT
Warfarin vs No
1.71 [0.64-4.58]
anticoagulation
LMWH vs No
1.2 [0.4-3.66]
anticoagulation
DOAC vs No
2.24 [0.73-6.86]
anticoagulation
Antiplatelet therapy
2.25 [1.05-4.81]*
CAD
0.9 [0.33-2.45]
History of cancer
0.84 [0.42-1.67]

Recurrent VTE

Mortality

1.12 [0.55-2.29]
1 [0.98-1.01]
1.18 [0.73-1.92]

0.79 [0.49-1.27]
1.04 [1.03-1.06]*
1.03 [0.71-1.47]

0.87 [0.5-1.52]

0.69 [0.47-1.03]

1.13 [0.67-1.91]

0.53 [0.35-0.8]*

1.52 [0.63-3.67]

0.19 [0.12-0.3]*

1.76 [0.59-5.29]

0.61 [0.34-1.07]

1.48 [0.54-4.03]

0.16 [0.09-0.3]*

0.83 [0.46-1.49]
0.65 [0.26-1.61]
0.58 [0.32-1.08]

0.57 [0.37-0.87]*
3.12 [1.80-5.41]*
4.26 [2.91-6.25]*

*Statistically significant P < .05; DVT: deep vein thrombosis, PE: pulmonary embolism,
LMWH: Low molecular weight heparin, CAD: coronary artery disease, DOAC: directacting oral anticoagulant; Odds Ratio [95% Confidence Interval]
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Supplement Table 1: Patient characteristics of those who received repeat
ultrasound after one month from DVT diagnosis

Age (years ± SD)
Female
Hypertension
Diabetes
Hyperlipidemia
CHF
CAD
PAD
CVD
Hypercoagulable disorder
History of prior DVT
History of prior PE
History of cancer
History of smoking
Antiplatelet therapy
Caprini score ± SD

Statin group
(n = 110)
% (n)
69 ± 13
50 (55)
75 (82)
45 (50)
75 (82)
17 (19)
26 (29)
9 (10)
23 (25)
4 (4)
22 (24)
8 (9)
29 (32)
51 (56)
48 (53)
6.3 ± 3.1

Non-statin group
(n = 242)
% (n)
58 ± 17
54 (131)
49 (118)
13 (32)
11 (27)
8 (20)
7 (18)
2 (5)
5 (11)
8 (19)
22 (53)
11 (26)
36 (87)
54 (130)
21 (50)
6.0 ± 2.8

P value

<0.001*
0.47
<0.001*
<0.001*
<0.001*
0.013*
<0.001*
0.007*
<0.001*
0.14
0.99
0.46
0.21
0.62
<0.001*
0.36

*Statistically significant P < .05; SD: standard deviation, DVT: deep vein thrombosis,
PE: pulmonary embolism, CHF: congestive heart failure, CAD: coronary artery disease,
PAD: peripheral arterial disease, CVD: cerebral vascular disease
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Supplement Table 2: DVT characteristics and treatment of patients who received
repeat ultrasound after one month from DVT incident

Provoked DVT
DVT location
Distal
Proximal
DVT associated with PE
Severity of PE
Low risk
Intermediate risk
High risk
Anticoagulation
None
Warfarin
LMWH
DOAC
Duration of anticoagulation
< 3 months
3-6 months
6-12 months
> 12 months
Not available
Placement of IVC filter
Catheter-directed thrombolysis of DVT
Catheter-directed thrombolysis of PE
Systemic administration of thrombolytic agent

Statin
group
(n = 110)
% (n)
51 (56)

Non-statin
group
(n = 242)
% (n)
49 (118)

23 (25)
77 (85)
22 (24)

30 (72)
70 (170)
22 (54)

46 (11)
29 (7)
25 (6)

44 (24)
43 (23)
13 (7)

11 (12)
60 (66)
13 (14)
16 (18)

10 (24)
52 (127)
17 (42)
20 (49)

P value
0.71
0.17

0.92
0.33

0.48

0.69
15 (15)
22 (22)
33 (32)
24 (24)
5 (5)
32 (35)
5 (5)
0 (0)
2 (2)

14 (30)
28 (62)
27 (58)
24 (53)
7 (15)
29 (70)
2 (6)
3 (7)
2 (4)

0.58
0.33
0.1
1

*Statistically significant P < .05; LMWH: low molecular weight heparin, DOAC: directacting oral anticoagulant, IVC: inferior vena cava, DVT: deep vein thrombosis, PE:
pulmonary embolism
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Supplement Table 3: Long-term outcomes of patients who received repeat
ultrasound after one month from DVT incident

Days to last follow-up
Mean ± SD
Median (IQR)
Surviving patients at last follow up
New or recurrent DVT
New or recurrent PE
Recurrent VTE
Mortality

Statin group
(n = 110)
% (n)

Non-statin group
(n = 242)
% (n)

1042 ± 433
1235 (723–1347)
80 (88)
28 (31)
2 (2)
29 (32)
20 (22)

1029 ± 432
1200 (697–1337)
80 (194)
32 (77)
5 (13)
33 (81)
20 (48)

P value
0.78
0.51
0.49
0.16
0.41
0.97

DVT: deep vein thrombosis, PE: pulmonary embolism, VTE: venous thromboembolism,
SD: Standard deviation
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Supplement Table 4: Patient characteristics of those who received repeat
ultrasound after one month from DVT diagnosis versus those who did not

Age (years ± SD)
Female
Hypertension
Diabetes
Hyperlipidemia
CHF
CAD
PAD
CVD
Hypercoagulable disorder
History of prior DVT
History of prior PE
History of cancer
History of smoking
Antiplatelet therapy
Caprini score ± SD

Repeat US after
one month
(n = 352)
% (n)
61 ± 16
53 (186)
57 (200)
23 (82)
31 (109)
11 (39)
13 (47)
4 (15)
10 (36)
7 (23)
22 (77)
10 (35)
34 (119)
53 (186)
29 (103)
6.1 ± 2.9

No repeat US
after one month
(n = 466)
% (n)
69 ± 16
50 (232)
64 (297)
25 (115)
37 (172)
14 (64)
22 (102)
5 (21)
13 (59)
5 (21)
16 (73)
10 (46)
49 (229)
58 (271)
34 (158)
6.7 ± 2.9

P value

<0.001*
0.39
0.04*
0.63
0.07
0.25
0.002*
0.87
0.28
0.2
0.02
0.97
<0.001*
0.13
0.16
0.004*

*Statistically significant P < .05; SD: standard deviation, DVT: deep vein thrombosis,
PE: pulmonary embolism, CHF: congestive heart failure, CAD: coronary artery disease,
PAD: peripheral arterial disease, CVD: cerebral vascular disease
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Supplement Table 5: DVT characteristics and treatment of patients who received
repeat ultrasound after one month from DVT incident

Provoked DVT
DVT location
Distal
Proximal
DVT associated with PE
Severity of PE
Low risk
Intermediate risk
High risk
Anticoagulation
None
Warfarin
LMWH
DOAC
Placement of IVC filter
Catheter-directed thrombolysis of DVT
Catheter-directed thrombolysis of PE
Systemic administration of thrombolytic agent

Repeat US
after one
month
(n = 352)
% (n)
49 (174)

No repeat
US after one
month
(n = 466)
% (n)
51 (237)

28 (97)
72 (255)
22 (78)

25 (116)
75 (349)
29 (137)

45 (35)
38 (30)
17 (13)

34 (46)
51 (69)
15 (21)

P value
0.66
0.4

0.02*
0.2

<0.001*
10 (36)
55 (193)
16 (56)
19 (67)
30 (105)
3 (11)
2 (7)
2 (6)

30 (139)
43 (200)
18 (82)
10 (45)
26 (122)
1 (3)
1 (5)
2 (8)

0.25
0.007*
0.28
0.99

*Statistically significant P < .05; LMWH: low molecular weight heparin, DOAC: directacting oral anticoagulant, IVC: inferior vena cava, DVT: deep vein thrombosis, PE:
pulmonary embolism
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Supplement Table 6: Long-term outcomes of patients who received repeat
ultrasound after one month from DVT incident versus those who did not

Days to last follow-up ± SD
New or recurrent DVT
New or recurrent PE
Recurrent VTE
Mortality

Repeat US after
one month
(n = 352)
% (n)
1033 ± 432
31 (108)
4 (15)
32 (113)
20 (70)

No repeat US
after one month
(n = 466)
% (n)
485 ± 541
2 (10)
2 (9)
4 (17)
52 (242)

P value
<0.001*
<0.001*
0.05
<0.001*
<0.001*

DVT: deep vein thrombosis, PE: pulmonary embolism, VTE: venous thromboembolism,
SD: Standard deviation
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Supplement Table 7: Thrombus resolution or improvement by time to repeat
ultrasound

Time to
repeat
US

< 1 year
1–2
years
2–3
years
3–4
years
>4
years

Statin group
(n = 110)

Non-statin group
(n = 242)

Resolved /
Improved
(n = 93)
% (n)
59 (10)

Stable /
Progression
(n = 17)
% (n)
41 (7)

Resolved /
Improved
(n = 187)
% (n)
65 (20)

Stable /
Progression
(n = 55)
% (n)
35 (11)

91 (10)

9 (1)

58 (18)

85 (11)

15 (2)

87 (48)
100 (14)

Total
cases
(n = 352)

P
value

% of
total (n)
13 (48)

0.69

42 (13)

12 (42)

0.07

83 (25)

17 (5)

12 (42)

1.00

13 (7)

83 (104)

18 (22)

51 (181)

0.51

0 (0)

83 (20)

17 (4)

11 (38)

0.28

